Potential Treatment for Chikungunya Discovered, A*STAR and Vivalis Reveal  
2/28/2011 7:17:34 AM

ScienceDaily (Feb. 15, 2011) — The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS (NYSE Euronext: VLS), a French biopharmaceutical company, has announced the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.